Special Issue "Proteomic Cancer Biomarkers in Human Biofluids"


A special issue of Proteomes (ISSN 2227-7382).

Deadline for manuscript submissions: closed (31 July 2015)

Special Issue Editor

Guest Editor
Prof. Dr. Michael A. Tainsky

Department of Oncology, Wayne State University, School of Medicine, 110 E. Warren Avenue, PR03GL, Detroit, MI 48201, USA
Website: http://cancerbiologyprogram.med.wayne.edu/faculty/tainsky.php
Interests: cancer-specific proteomes; protein biomarkers; tissue-specific biofluids; multianalyte biomarker panels; presymptomatic cancer diagnostics

Special Issue Information

Dear Colleagues,

The National Cancer Institute at the National Institutes of Health defines a biomarker as a “biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease”. Biomarkers can provide molecular signals of the status of a disease as well as provide information for targeted therapeutic interventions. The host response to cancer-specific proteins also provides diagnostic indicators suitable for monitoring tumor burden and the effectiveness of clinical interventions. Biomarkers have been employed to stratify cancer patients to the most effective treatment. Biomarkers for the early detection of cancer must result in a reduction in disease-specific mortality from cancer otherwise the medical community cannot be expected to adopt their use. Researchers now recognize that panels of biomarker analytes rather than single markers will be needed to have sufficient sensitivity and specificity for the presymptomatic detection of cancer. Proteomics studies have shown that there is considerable overlap of protein biomarkers even among unrelated tumors such that additional approaches are needed for tissue specificity.
One solution to the dilemma of specificity is to perform biomarker studies in biofluids other than serum or plasma. Because of the ease of using serum or plasma, most cancer biomarker studies utilize these biofluids. However, using other biofluids physiologically associated with a particular tissue may provide more organ specific tumor biomarkers. With this in mind we have primarily focused this issue on the use of nontraditional biofluids for cancer proteomic screening modalities and secondarily on biomarker proteins other than those secreted from tumor cells because they tend to identify cases with large, late stage tumors. Ideally a biomarker screening panel should identify a specific cancer sufficiently early when treatments can result in an increase in progression-free survival rather than simply a lead-time bias.

Prof. Dr. Michael A. Tainsky
Guest Editor


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Proteomes is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.


  • organ specific tumor biomarkers
  • early detection of cancer
  • biomarker screening panel
  • cancer-specific proteins
  • presymptomatic detection of cancer
  • biomarkers for targeted therapeutic interventions

Published Papers (3 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-3
p. 266-282
by , , , , , , ,  and
Proteomes 2015, 3(3), 266-282; doi:10.3390/proteomes3030266
Received: 30 June 2015 / Revised: 25 August 2015 / Accepted: 27 August 2015 / Published: 3 September 2015
Show/Hide Abstract | PDF Full-text (415 KB) | HTML Full-text | XML Full-text | Supplementary Files
(This article belongs to the Special Issue Proteomic Cancer Biomarkers in Human Biofluids)
p. 426-450
by ,  and
Proteomes 2014, 2(3), 426-450; doi:10.3390/proteomes2030426
Received: 4 February 2014 / Revised: 7 April 2014 / Accepted: 5 August 2014 / Published: 13 August 2014
Show/Hide Abstract | PDF Full-text (2776 KB) | HTML Full-text | XML Full-text | Supplementary Files
(This article belongs to the Special Issue Proteomic Cancer Biomarkers in Human Biofluids)
p. 1-17
by  and
Proteomes 2014, 2(1), 1-17; doi:10.3390/proteomes2010001
Received: 26 November 2013 / Revised: 17 December 2013 / Accepted: 8 January 2014 / Published: 13 January 2014
Show/Hide Abstract | Cited by 1 | PDF Full-text (1167 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Proteomic Cancer Biomarkers in Human Biofluids)
abstract graphic
Select/unselect all
Displaying article 1-3
Select articles Export citation of selected articles as:

Last update: 23 March 2015

Proteomes EISSN 2227-7382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert